Acta microbiologica et immunologica Hungarica最新文献

筛选
英文 中文
Rebuilding the gut ecosystem: Emerging strategies targeting the microbiota in antibiotic-associated diarrhea. 重建肠道生态系统:针对抗生素相关性腹泻中微生物群的新兴策略。
IF 1.6 4区 医学
Acta microbiologica et immunologica Hungarica Pub Date : 2025-10-21 Print Date: 2025-11-27 DOI: 10.1556/030.2025.02690
Xubin Qi, Yu Li, Yaqin Zhu, Rui Shen, Zhuoxin Xie
{"title":"Rebuilding the gut ecosystem: Emerging strategies targeting the microbiota in antibiotic-associated diarrhea.","authors":"Xubin Qi, Yu Li, Yaqin Zhu, Rui Shen, Zhuoxin Xie","doi":"10.1556/030.2025.02690","DOIUrl":"10.1556/030.2025.02690","url":null,"abstract":"<p><p>Antibiotic-associated diarrhea (AAD) is a prevalent iatrogenic complication of antibiotic therapy, primarily triggered by dysbiosis and loss of intestinal homeostasis. The traditional interventions, such as empirical probiotic use, have shown a modest and a heterogeneous efficacy. This review integrates the current mechanistic understanding of AAD through the lens of the microbiota-mucosal-immune axis and provides a comprehensive overview of emerging therapeutic strategies. By integrating evidence from metagenomics, metabolomics, and immunology, we highlight next-generation approaches, including rationally engineered probiotics, standardized fecal microbiota transplantation (FMT), and synthetic-biology-derived interventions. Recent progress in multi-omics technologies and machine learning has enabled patient-stratified modulation of the gut microbiota, moving beyond empirical supplementation toward precision ecological reprogramming. These advanced therapies demonstrate superior outcomes in restoring microbial diversity, strengthening epithelial barrier function, and re-establishing immunological homeostasis. Ultimately, the management of AAD requires a systems-biology strategy that leverages real-time microbiome analytics for targeted, accurate, and sustainable restoration of gut health.</p>","PeriodicalId":7119,"journal":{"name":"Acta microbiologica et immunologica Hungarica","volume":" ","pages":"287-295"},"PeriodicalIF":1.6,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145342598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of intestinal colonization by multidrug-resistant bacteria and related bloodstream infections in patients with hematological malignancies. 血液系统恶性肿瘤患者肠道定植耐多药细菌和相关血流感染的患病率
IF 1.6 4区 医学
Acta microbiologica et immunologica Hungarica Pub Date : 2025-10-16 Print Date: 2025-11-27 DOI: 10.1556/030.2025.02730
Temenuga Stoeva, Denis Niyazi, Lyuben Stoev, Klara Dokova
{"title":"Prevalence of intestinal colonization by multidrug-resistant bacteria and related bloodstream infections in patients with hematological malignancies.","authors":"Temenuga Stoeva, Denis Niyazi, Lyuben Stoev, Klara Dokova","doi":"10.1556/030.2025.02730","DOIUrl":"10.1556/030.2025.02730","url":null,"abstract":"<p><p>The aim of this study was to investigate the prevalence of intestinal colonization by major multidrug-resistant (MDR) bacteria and fungi in patients with hematological malignancies (HM) and its relationship with subsequent bloodstream infections (BSIs). The study was performed between December 2023 and June 2024 at the University Hospital \"Saint Marina\", Varna, Bulgaria. A total of 180 HM patients were screened for intestinal colonization by 3rd generation cephalosporin-resistant (3rdGCephR) and carbapenem-resistant (CR) Enterobacterales, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Vancomycin-Resistant Enterococci (VRE) and Candida sp. according to our own protocol. Blood cultures were taken according to clinical indications. Multiplex PCR was used to detect beta-lactamase genes in all invasive Enterobacterales isolates. A total of 100 patients (55.6%) were colonized by one or more of the screened agents. Among these, 88 patients were MDR carriers (48.9%, 88/180) and the highest colonization rates were found for CR Klebsiella pneumoniae (CRKP) (42%), Candida sp. (34%), VRE (25%) and 3rdGCephR Escherichia coli (23%). A total of 29 patients (16.1%; 29/180) developed BSIs, with K. pneumoniae responsible for 44.8%. Of these, 76.9% (10/13) were CR and blaNDM positive isolates. Related BSIs were diagnosed in 57.9% of the MDR carriers with BSIs (11/19). The related BSIs percentage according to the colonizing agent was 21.4% for CRKP (9/42), 7.1% for 3rdGCephR K. pneumoniae (1/14) and 25% for P. aeruginosa (1/4). CRKP colonization was significantly higher among patients with CRKP BSIs than those with non-CRKP BSIs (P < 0.001). The MDR intestinal colonization, specifically by CRKP is an important source for subsequent BSIs in this high-risk patient population.</p>","PeriodicalId":7119,"journal":{"name":"Acta microbiologica et immunologica Hungarica","volume":" ","pages":"341-349"},"PeriodicalIF":1.6,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145306721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Large-scale seroepidemiology of human cytomegalovirus (CMV) in Hungary (2010-2024). 匈牙利人巨细胞病毒(CMV)的大规模血清流行病学(2010-2024)
IF 1.6 4区 医学
Acta microbiologica et immunologica Hungarica Pub Date : 2025-10-14 Print Date: 2025-11-27 DOI: 10.1556/030.2025.02726
Benigna Balázs, Ákos Boros, Péter Pankovics, Gábor Reuter
{"title":"Large-scale seroepidemiology of human cytomegalovirus (CMV) in Hungary (2010-2024).","authors":"Benigna Balázs, Ákos Boros, Péter Pankovics, Gábor Reuter","doi":"10.1556/030.2025.02726","DOIUrl":"10.1556/030.2025.02726","url":null,"abstract":"<p><p>Despite the clinical importance of the human cytomegalovirus (CMV) infections especially in pregnant women and immunocompromised patients, there are only a few CMV seroprevalence studies in certain risk groups from Hungary. In this study, the results of CMV-specific IgG antibody tests were analysed by calendar year, gender, and 5-year age groups (from 0 to 97) among the population of South Transdanubia, Hungary from blood samples (N = 13,777), between January 1, 2010, and December 31, 2024, covering 15-years.The average CMV-specific IgG seropositivity was 69.2% (9,522/13,761 patients), which increased with age between 31 and 50 years (+∼1%/year). Seroprevalence was lowest (37.8%) in the 1-5 age group, reached 50% in the 21-25 age group, and exceeded 80% in those over 50 years. In certain age groups (16-20, 26-30, 46-50, 51-55, and 66-70 years old), CMV seroprevalence was significantly higher among women. Women of child-bearing age between 16 and 45 years showed 61.2% seroprevalence. Between 2020 and 2023, the yearly CMV seroprevalence decreased (from 70.8 to 64.7%) by ∼6%.This summary of CMV IgG seroprevalence fills gaps in terms of both the number of elements, the size of the studied population, and its age diversity in Hungary. The average CMV seropositivity in South Transdanubia follows the level of socio-economic development of the countries. Basic knowledge of CMV seroepidemiological data helps physicians with CMV risk assessment and find the optimal infection prevention strategies in different age and sex groups.</p>","PeriodicalId":7119,"journal":{"name":"Acta microbiologica et immunologica Hungarica","volume":" ","pages":"380-385"},"PeriodicalIF":1.6,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145290617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of psychosomatic interventions on the immune system and gut microbiome diversity of pregnant women with gestational hypertension. 心身干预对妊娠期高血压孕妇免疫系统和肠道微生物多样性的影响
IF 1.6 4区 医学
Acta microbiologica et immunologica Hungarica Pub Date : 2025-10-13 Print Date: 2025-11-27 DOI: 10.1556/030.2025.02688
Wenwen Gu, Juan Wang, Xia Yuan
{"title":"The role of psychosomatic interventions on the immune system and gut microbiome diversity of pregnant women with gestational hypertension.","authors":"Wenwen Gu, Juan Wang, Xia Yuan","doi":"10.1556/030.2025.02688","DOIUrl":"10.1556/030.2025.02688","url":null,"abstract":"<p><p>This study evaluates the impact of psychosomatic interventions on the immune system and microbiome composition of pregnant women diagnosed with gestational hypertension. A case-control study on 200 pregnant women diagnosed with gestational hypertension was conducted between June 2021 and December 2024. The control group (n = 100) included pregnant women diagnosed with gestational hypertension and under only pharmacological treatment with antihypertensive drugs such as labetalol. The case group (n = 100) received standard care for hypertensive disorders in pregnancy like control group, but in addition to it, we incorporated evidence based psychosomatic medicine to this group. Psychosomatic medicine included stress management, relaxation techniques, and counseling for the study group. Primary outcomes included blood pressure levels, psychological state (SAS and SDS scores), mode of delivery, incidence of complications, neonatal outcomes, patient satisfaction, reductions in inflammatory cytokines (e.g., IL-6, TNF-alpha), and improvements in microbiome diversity. Psychosomatic intervention led to a significant increase in microbiome diversity (Shannon Index, P < 0.05). Beta-diversity analysis revealed a distinct separation in microbial community composition between the study and control groups (P = 0.02). The case group also showed a reduction in pro-inflammatory cytokines, IL-6 decreased from 40.0 to 28.0 pg mL-1 (P = 0.008) and TNF-alpha from 25.0 to 18.0 pg mL-1 (P = 0.004). The case group demonstrated significant improvements in systolic (P = 0.020) and diastolic (P = 0.003) blood pressures, psychological well-being (SAS, P = 0.006; SDS: P = 0.026), and delivery outcomes (P = 0.032). Complications were significantly lower in the case group (P = 0.013), with better neonatal outcomes, including lower rates of intrauterine distress (P = 0.011), premature birth (P = 0.003), and asphyxia (P = 0.013). Emotional resilience, coping confidence, and patient satisfaction were significantly higher in the case group (P < 0.05). These findings suggest that psychosomatic medicine may offer a novel approach for managing gestational hypertension through microbiome modulation.</p>","PeriodicalId":7119,"journal":{"name":"Acta microbiologica et immunologica Hungarica","volume":" ","pages":"321-330"},"PeriodicalIF":1.6,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145285217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2bRAD-M sequencing reveals differences in serum, tumor and paraneoplastic tissue microbiota in colorectal cancer patients. 2bRAD-M测序揭示了结直肠癌患者血清、肿瘤和副肿瘤组织微生物群的差异。
IF 1.6 4区 医学
Acta microbiologica et immunologica Hungarica Pub Date : 2025-10-03 Print Date: 2025-10-09 DOI: 10.1556/030.2025.02675
Sun Wenchang, Yan Shushan, Zhao Lu, Lv Qianwen, Zhao Chunbo, Dai Wenqing, Zhang Yan, Li Wanxiang, Wang Honggang
{"title":"2bRAD-M sequencing reveals differences in serum, tumor and paraneoplastic tissue microbiota in colorectal cancer patients.","authors":"Sun Wenchang, Yan Shushan, Zhao Lu, Lv Qianwen, Zhao Chunbo, Dai Wenqing, Zhang Yan, Li Wanxiang, Wang Honggang","doi":"10.1556/030.2025.02675","DOIUrl":"10.1556/030.2025.02675","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is a malignant disease associated with substantial morbidity and mortality rates, and the implementation of early screening has been shown to greatly enhance survival outcomes. Currently, early screening methods for CRC rely on stool-based tests and colonoscopy; however, the limited adherence of patients to these screening protocols hinders their widespread adoption. The utilization of innovative microbiological sequencing technique known as 2bRAD-M holds promise for the detection of low biomass samples. In this study, the 2bRAD-M technique was employed to ascertain a diverse microbiota consisting of different microorganisms in the serum of patients diagnosed with CRC, as well as in the serum of healthy control individuals. This study included 3 patients with non-metastatic CRC and 3 healthy individuals. Additionally, the microbiota present in CRC tumor tissues and paraneoplastic tissues were also examined. Furthermore, the metabolic pathways of these microorganisms were predicted. The findings indicated that the microbiota community structures in serum and tissues were distinct, while the microbiota composition in tumor tissues and adjacent tissues was largely similar. Microbiota in serum such as Enterobacteriaceae and tissue-associated RC9、Ralstonia may serve as novel biomarkers for CRC screening. Our results suggest that both serum microbiota and cancer tissue microbiota can serve as a valuable basis for conducting early in vitro screening for CRC.</p>","PeriodicalId":7119,"journal":{"name":"Acta microbiologica et immunologica Hungarica","volume":" ","pages":"203-211"},"PeriodicalIF":1.6,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145224627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigations of Escherichia coli ST131 and H30Rx subclone from clinical samples. 临床标本中大肠杆菌ST131和H30Rx亚克隆的研究。
IF 1.6 4区 医学
Acta microbiologica et immunologica Hungarica Pub Date : 2025-09-30 Print Date: 2025-10-09 DOI: 10.1556/030.2025.02710
Elif Aydin, Selahattin Celebi, Ozgur Celebi, Demet Celebi, Ali Taghizadehghalehjoughi
{"title":"Investigations of Escherichia coli ST131 and H30Rx subclone from clinical samples.","authors":"Elif Aydin, Selahattin Celebi, Ozgur Celebi, Demet Celebi, Ali Taghizadehghalehjoughi","doi":"10.1556/030.2025.02710","DOIUrl":"10.1556/030.2025.02710","url":null,"abstract":"<p><p>Escherichia coli is a highly adaptable Gram-negative bacterium, commonly part of the gut microbiota in humans and animals, yet capable of causing severe extraintestinal infections. Among its lineages, Sequence Type 131 (ST131) has emerged as a globally disseminated, multidrug-resistant, high-risk clone with remarkable capacity for systemic infections. This study provides a comprehensive molecular epidemiological characterization of 160 clinical E. coli isolates, collected between 15.09.2021 and 28.02.2022, assessing antimicrobial resistance profiles, virulence gene carriage, phylogenetic group distribution, prevalence of ST131 and H30Rx subclone, and biofilm-forming capacity. Isolates were identified by conventional and automated methods, with molecular analyses performed via in-house PCR assays. Our results reveal a striking 69.38% prevalence of ST131, with 95.5% harboring virulence genes and 81.99% exhibiting biofilm formation. Notably, ST131-positive isolates demonstrated extensive resistance to multiple antimicrobial classes, including ESBL production, and were dominated by the H30Rx subclone. Specifically, 73.87% of ST131 isolates were ESBL-positive, fluoroquinolone resistance was observed in 81.37%, while aminoglycoside resistance rate remained very low. The H30Rx subclone was strongly associated with ESBL positivity and multidrug resistance. Moreover, integron carriage diversity and strong association with fimA virulence gene further highlight the adaptive versatility of this clone. Given that ST131 and its H30Rx subclone are recognized as global pandemic lineages associated with multidrug resistance and severe infections, their detection in our cohort emphasizes both the clinical relevance and the public health risk posed by these clones. Our findings underscore the urgent need for targeted surveillance and control strategies, offering novel epidemiological insights into the molecular diversity and clinical threat posed by E. coli ST131 in Turkey.</p>","PeriodicalId":7119,"journal":{"name":"Acta microbiologica et immunologica Hungarica","volume":" ","pages":"226-236"},"PeriodicalIF":1.6,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145197611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics of pertussis in children: A retrospective study of 306 cases in Wuxue, China. 中国武雪地区306例儿童百日咳的特点回顾性分析。
IF 1.6 4区 医学
Acta microbiologica et immunologica Hungarica Pub Date : 2025-09-30 Print Date: 2025-11-27 DOI: 10.1556/030.2025.02683
Jie Chen, Ming Zhang, Yantao Wu, Qian Zhang
{"title":"Characteristics of pertussis in children: A retrospective study of 306 cases in Wuxue, China.","authors":"Jie Chen, Ming Zhang, Yantao Wu, Qian Zhang","doi":"10.1556/030.2025.02683","DOIUrl":"10.1556/030.2025.02683","url":null,"abstract":"<p><p>We investigated the epidemiological and clinical characteristics of pertussis in children from Wuxue, China, focusing on age-specific patterns in clinical presentation, laboratory findings and outcomes. A retrospective case-control study was conducted on 306 pediatric patients hospitalized with pertussis at Wuxue First People's Hospital between May 2023 and June 2024. Patients were stratified into three age groups: infants (2-12 months, n = 82), preschool children (1-6 years, n = 127), and school-aged children (7-13 years, n = 97). Age-matched healthy controls (n = 306) were included for hematological comparisons. Data were analyzed using SPSS 22.0 and GraphPad Prism 9.5.0. Infants exhibited the most severe clinical profiles, with significantly elevated leukocyte and lymphocyte parameters compared to older groups (P < 0.001). The incidence of pneumonia was the highest in infants (82.93% vs. 33.07% in preschool and 22.68% in school-aged children, P < 0.001). ROC analysis highlighted lymphocyte percentage as a reliable diagnostic marker in infants (AUC = 0.7620). Seasonal peaks occurred in spring (61.44%) and winter (20.91%). Notably, 84.32% of infected children were fully vaccinated, indicating waning immunity. Macrolide-resistant Bordetella pertussis strains were identified in 7.19% of cases however, co-trimoxazole was effective against these resistant strains. Severe pertussis occurred in 14.05% of cases, predominantly in infants (81.40%, P < 0.001). Age is a critical factor in pertussis presentation. The high vaccination rate among cases underscores issues of waning immunity, necessitating updated immunization strategies. Emerging macrolide resistance warrants vigilance, with co-trimoxazole serving as an effective alternative for therapy. Infants require prioritized surveillance and prompt management.</p>","PeriodicalId":7119,"journal":{"name":"Acta microbiologica et immunologica Hungarica","volume":" ","pages":"331-340"},"PeriodicalIF":1.6,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145197642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antimicrobial resistance rates of Campylobacter species isolated from clinical samples during 2010-2011 and 2023-2024 in Serbia. 2010-2011年和2023-2024年塞尔维亚临床标本分离弯曲杆菌的耐药性
IF 1.6 4区 医学
Acta microbiologica et immunologica Hungarica Pub Date : 2025-09-25 Print Date: 2025-10-09 DOI: 10.1556/030.2025.02685
Zoran Tambur, Biljana Miljković-Selimović, Vladimir Biočanin, Ivan Stanojević, D Kljajić, Bojan Rakonjac, Nina Bulajić
{"title":"Antimicrobial resistance rates of Campylobacter species isolated from clinical samples during 2010-2011 and 2023-2024 in Serbia.","authors":"Zoran Tambur, Biljana Miljković-Selimović, Vladimir Biočanin, Ivan Stanojević, D Kljajić, Bojan Rakonjac, Nina Bulajić","doi":"10.1556/030.2025.02685","DOIUrl":"10.1556/030.2025.02685","url":null,"abstract":"<p><p>Campylobacteriosis is the most frequent zoonosis in Europe and its most important human pathogens are Campylobacter jejuni and Campylobacter coli. Resistance of Campylobacter to fluoroquinolones and tetracyclines, previously recommended for treatment of prolonged or complicated disease, has been emerging. We examined phenotypic resistance to erythromycin, tetracycline, ciprofloxacin, gentamicin, amoxicillin-clavulanic acid and imipenem in 150 Campylobacter isolates from human stool during 2010-2011 and the same number of strains during 2023-2024, using the antimicrobial gradient method in both periods, to determine minimum inhibitory concentration (MIC). Comparing the two periods, resistance rate of C. jejuni increased by 35% and 38.43% to tetracyclin and ciprofloxacin, respectively and decreased by 0.83% to erythromycin. Prevalence of resistance in C. coli increased by 42.59% and 42.01% against tetracyclin and ciprofloxacin, respectively and all isolates were sensitive to erythromycin. Resistance of C. jejuni to amoxicillin-clavulanic acid decreased by 0.96% and increased by 3.70% in C. coli. All isolates showed sensitivity for imipenem in both periods, while only 2% of C. jejuni strains were resistant to gentamicin in 2023-2024. The difference of mean MICs for all antibiotics was statistically significant in two examined periods, with exception of those for erythromycin both in C. jejuni and C. coli. In 2023-2024, 79 isolates of C. jejuni and 22 isolates of C. coli were resistant against two and more antibiotics, most frequently tetracycline and ciprofloxacin. The present study provides evidence that in Campylobacter spp. the antimicrobial resistance to ciprofloxacin and tetracycline is on rise in Serbia. Our findings are in accordance with recent reports from countries geographically close to Serbia.</p>","PeriodicalId":7119,"journal":{"name":"Acta microbiologica et immunologica Hungarica","volume":" ","pages":"256-260"},"PeriodicalIF":1.6,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145147273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cefiderocol as an alternative antibiotic therapy for treating severe Stenotrophomonas maltophilia infections. 头孢地罗作为治疗严重嗜麦芽窄养单胞菌感染的替代抗生素。
IF 1.6 4区 医学
Acta microbiologica et immunologica Hungarica Pub Date : 2025-09-16 Print Date: 2025-10-09 DOI: 10.1556/030.2025.02676
Paiboon Vattanaviboon, Skorn Mongkolsuk, Nisanart Charoenlap
{"title":"Cefiderocol as an alternative antibiotic therapy for treating severe Stenotrophomonas maltophilia infections.","authors":"Paiboon Vattanaviboon, Skorn Mongkolsuk, Nisanart Charoenlap","doi":"10.1556/030.2025.02676","DOIUrl":"10.1556/030.2025.02676","url":null,"abstract":"<p><p>Stenotrophomonas maltophilia has emerged as an opportunistic pathogen that causes life-threatening hospital-acquired infections. This microorganism possesses a diverse array of chromosome-encoded antimicrobial resistance genes, which render it inherently multidrug-resistant (MDR). Its ability to acquire additional antimicrobial resistance via mutations and the horizontal transfer of resistome elements from neighboring microbial communities has further contributed to the development of extensively drug-resistant (XDR) and even pandrug-resistant (PDR) strains. These strains are resistant to routinely used antibiotics, including the first-line drug trimethoprim/sulfamethoxazole as well as levofloxacin and minocycline. Recently, cefiderocol - a siderophore-conjugated cephalosporin - was developed for clinical use. This antibiotic has shown high in vitro efficacy against clinically relevant MDR gram-negative pathogens. Cefiderocol efficiently transverses the outer membrane of bacteria via iron transport systems and exhibits high stability against β-lactamases. An injectable form of cefiderocol has received Food and Drug Administration approval for the treatment of complicated urinary tract infections, hospital-acquired bacterial pneumonia, and ventilator-associated bacterial pneumonia caused by drug-resistant gram-negative bacteria. Clinical data on the use of cefiderocol for S. maltophilia infections remain limited, however, some in vitro, in vivo, and case studies have demonstrated its efficacy and successful treatment of MDR S. maltophilia infections. Given the narrow range of therapeutic options currently available, cefiderocol presents a promising alternative for the effective management of severe S. maltophilia infections. Nevertheless, the potential for the emergence of resistance remains a significant concern, as emerging evidence suggests that S. maltophilia may acquire resistance following exposure to this antibiotic.</p>","PeriodicalId":7119,"journal":{"name":"Acta microbiologica et immunologica Hungarica","volume":" ","pages":"171-179"},"PeriodicalIF":1.6,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Activity of ceftazidime-avibactam combinations against carbapenem-resistant Klebsiella pneumoniae assessed by checkerboard method. 棋盘法评价头孢他啶-阿维巴坦联合用药对耐碳青霉烯肺炎克雷伯菌的活性。
IF 1.6 4区 医学
Acta microbiologica et immunologica Hungarica Pub Date : 2025-09-16 Print Date: 2025-10-09 DOI: 10.1556/030.2025.02686
Serpil Genç, Ayten Nur Uzun, Hilal Tanriverdi
{"title":"Activity of ceftazidime-avibactam combinations against carbapenem-resistant Klebsiella pneumoniae assessed by checkerboard method.","authors":"Serpil Genç, Ayten Nur Uzun, Hilal Tanriverdi","doi":"10.1556/030.2025.02686","DOIUrl":"10.1556/030.2025.02686","url":null,"abstract":"<p><p>The aim of this study is to detect the carbapenemase type and to determine the in vitro effects of ceftazidime/avibactam-colistin, ceftazidime/avibactam-meropenem and ceftazidime/avibactam-tigecycline combinations against Carbapenem-Resistant Klebsiella pneumoniae (CRKP) isolates. A total of 35 CRKP isolates were included to the study. The minimum inhibitory concentrations of ceftazidime/avibactam, meropenem, colistin and tigecycline were determined by broth dilution method. Synergistic effects of ceftazidime/avibactam-colistin, ceftazidime/avibactam-meropenem and ceftazidime/avibactam-tigecycline were investigated by microdilution checkerboard method. Carbapenemase genes (blaOXA-48, blaNDM, blaKPC, blaIMP, blaVIM) were detected by multiplex PCR. All of the isolates were resistant to meropenem, whereas 77.1% of the isolates were resistant to ceftazidime/avibactam and 14.3% of the isolates were resistant to colistin.The carbapenemase genes of the CRKP isolates were determined as 17 OXA-48+NDM, 9 KPC, 6 OXA-48, 1 NDM, 1 KPC+NDM and 1 KPC+OXA-48. Ceftazidime/avibactam-colistin, ceftazidime/avibactam-meropenem and ceftazidime/avibactam-tigecycline combinations were synergistic against 5.7% (2/35), 17.1% (6/35), and 5.7% (2/35) of the isolates, respectively. Ceftazidime/avibactam-meropenem was the most effective synergistic combination in our study, showing synergism in 17.1% of isolates, however, the synergistic effect varied depending on the CRKP isolate tested.</p>","PeriodicalId":7119,"journal":{"name":"Acta microbiologica et immunologica Hungarica","volume":" ","pages":"220-225"},"PeriodicalIF":1.6,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书